Boston Scientific 10-Qquarter ended 2026-09-30

Executive Summary

Boston Scientific sells medical devices to hospitals and clinicians, earning revenue from products used in cardiovascular, digestive, urological and neurological procedures. It is expanding its treatment portfolio through product development and acquisitions, including the proposed $14.5B Penumbra purchase. An August cyberattack interrupted manufacturing and shipments, helping slow Q3 sales growth to 1.4% and compress margins, while competition and slower procedure growth also pressured key heart-treatment franchises. The opportunity is a broader portfolio of differentiated treatments; the investor challenge is separating temporary disruption from weakening demand as acquisition commitments increase.

What's Happening in the Business

The 8/25/2026 cyberattack disrupted global systems, production, order processing and shipments. Operations were restored within weeks, but Boston Scientific may not recover all displaced revenue. Idle production and supply-chain costs also hurt profitability, so restoring systems does not by itself establish that the commercial damage is over.

Product performance was uneven. AGENT drug-coated balloons and Neuromodulation’s Nalu, Intracept and deep brain stimulation products supported growth. Electrophysiology faced stronger competition, while slower growth in left atrial appendage closure procedures affected WATCHMAN. Urology also faced weakness in China’s stone-treatment business and commercial disruption in sacral neuromodulation.

Acquisitions are broadening the portfolio. Penumbra would join Cardiovascular; management expects closing in early 2027, but an FTC Second Request extends regulatory scrutiny. The planned funding includes ≈$11.0B of cash and newly issued debt, with the remainder in shares. Separately, Boston Scientific paid $1.5B to MiRus for an investment and exclusive option to acquire its transcatheter aortic valve replacement business; exercising that option would require another $3.0B, plus potential sales-based payments.

The July restructuring plan targets $500M in annual gross pretax savings, some to be reinvested in growth. Expected charges of $700M–$800M include $600M–$700M of cash outlays: improving the cost base requires substantial spending first.

Key Financial Highlights

Segment revenue below uses the filing’s internally derived constant-currency basis.

• Product drivers: Interventional Cardiology & Vascular Therapies generated $1.27B, +12%, and Neuromodulation $331M, +13%. These gains countered Electrophysiology at $816M, −5.7%, and WATCHMAN at $482M, −5.9%; both reversed positive 9M trends of +8.3% and +5.1%, respectively.
• Costs outside segments: Special charges totaled $302M vs $146M, including litigation of $81M, restructuring of $63M and intangible impairment of $39M. Corporate expenses fell to $196M from $299M, partly cushioning the impact; amortization was $234M.
• Tax benefit: A $383M discrete benefit reflected a revised expected tax rate on recovering capitalized expenses—not stronger device sales or operating efficiency.
• Cash generation: 9M OCF was $2.87B, −9.5%, against net income of $2.83B. Higher working-capital payments reduced cash generation while the tax adjustment boosted earnings; after $552M of capital spending, FCF was $2.32B, −12%.
• Capital allocation: Repurchases consumed $2.00B vs none a year earlier; shares outstanding fell ≈2.3% net of issuance. Acquisition and investment spending also reduced cash to $609M from $1.97B, while debt reached $12.0B, +4.5% since year-end.

Risk Assessment

• Cyber and production concentration: Unrecovered orders, remediation costs and civil claims could extend the attack’s consequences; manufacturing at one or a few sites limits alternatives during another disruption.
• Acquisition execution and funding: Penumbra faces extended regulatory review, substantial new financing and integration demands, while MiRus adds conditional future commitments.
• Competitive durability: Electrophysiology competition, slower WATCHMAN procedure growth and China procurement pressure could prevent sales from recovering fully after cyber disruption fades.
• Acquisition-heavy balance sheet: Goodwill and other intangibles leave only ≈$34M of tangible common equity, making further impairments consequential for reported equity.

This 10-Q lists only the risk factors that changed since the annual report. Full list: the company's 10-Ks on SEC.

What to Watch

• Operational recovery: Systems returned within weeks; later filings should show restored production, shipments and margins, or continuing lost orders and remediation costs.
• Cardiovascular demand: Electrophysiology and WATCHMAN declined despite positive YTD growth. Renewed growth would support a temporary-disruption explanation; continued weakness would point toward competition or market limits.
• Penumbra closing: Management expects early 2027 completion, subject to regulatory clearance. Approval and integration would expand Cardiovascular; delays, remedies or termination would change that strategy.
• Restructuring economics: The savings program succeeds if margins and cash generation improve while product investment continues; persistent charges without improvement would weaken its rationale.